Friday, February 12, 2010
Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype -- Journal of Clinical Pathology
Conclusion: Preoperative CA19.9 levels cannot be used to predict whether a suspected ovarian mucinous tumour is benign, borderline or malignant. Markedly elevated serum levels (>1000 U/ml) may be found in benign mucinous neoplasms as well as in borderline and malignant tumours.
Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot stud
Note: warning on stats
"Results: Overall, 36 OCR patients were enrolled. The majority of the patients (>80%) were classified as platinum resistant.....
Prospective phase III trials are warranted to evaluate the benefit and efficacy in heavily pre-treated patients with OCR."
Adverse events experienced by homecare patients: a scoping review of the literature
CONCLUSION: A standardized definition of adverse events in the homecare setting is needed. Prospective cohort studies are needed to improve estimates and intervention studies should be undertaken to reduce the risk that homecare patients will experience adverse events.
PharmaLive press release: Clinical Science to publish manuscript on HTX005 ovarian cancer biomarker 'OvPlex' (plus HTX005/AGR2)
Note: the abstract included here did not indicate the number of patients involved in the studies (see prior research articles) but according to the press release showed results in stages 11/111.
"10 February 2010, Melbourne: HealthLinx Limited (ASX:HTX) has been notified by the journal Clinical Science that a manuscript submitted for review by HealthLinx scientists and collaborators at the University of Liverpool has been accepted for publication. The manuscript describes the identification of HTX005 (AGR2) as a novel biomarker released into the bloodstream of ovarian cancer patients.
The performance of the novel biomarker AGR2 will be further tested in an up-coming multi-centre, multi-national biomarker study planned by HealthLinx. Based on preliminary data it is expected that this biomarker will increase the performance of OvPlex™ to greater than 97 per cent."
Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection, February 2, 2010 News Release - National Institutes of Health (NIH)
The team used this approach to screen blood specimens from breast, ovarian and prostate cancer patients.
Thursday, February 11, 2010
New ovarian cancer drug tested - 'Nanotax' news article Kansan
"The University of Kansas Cancer Center began running a Phase I clinical trial of the anti-ovarian cancer drug Nanotax. Nanotax is a breakthrough drug because, unlike other anti-cancer drugs, it is water-soluble....The clinical trial at the University comes nearly 15 year after Nanotax was first conceived. It is one of three active clinical trials for ovarian cancer treatment in Kansas, and it’s the only one still recruiting patients. The trial is classified as Phase I because it tests the drug in a small group.
Prevalence Rates of Pathogenic Mutations in the BRCA1 and BRCA2 Genes in Families with Different Disease Histories: Results from the German Consortium for Hereditary Breast and Ovarian Cancer
* From 1997-2009 more than 6,000 families were screened for pathogenic mutations in BRCA1/2.
Abstract Vitamin D: Panacea or a Pandora's box for prevention? CPR
"Among women, an increased rate of mortality was observed both for deficient concentrations and very high concentrations (>124nmol/L). Results suggest that caution should be exercised in using very high dose vitamin D supplementation in prevention trials that may result in high concentrations of vitamin D (>100nmol/L). Results suggest that caution should be exercised in using very high dose vitamin D supplementation in prevention trials that may result in high concentrations of vitamin D (>100nmol/L)."
Abstract - Cancer predisposition: I say genetics, you say genomics, but are we there yet? -- Cancer Prevention Research
"A few examples include Lynch syndrome, hereditary breast-ovarian cancer syndrome and Cowden syndrome."
Abstract: Risk factors for epithelial ovarian cancer by tumor dominance, a surrogate for cell of origin -Cancer Prevention Research
"Although limited by small case numbers, our results suggest that tubal ligation may be more strongly associated with tumors of ovarian origin, while family history of ovarian cancer primarily increases risk of tumors of tubal origin. Characterizing risk factor relationships by tumor dominance may elucidate how these exposures alter risk and help to improve prevention efforts."
short video: Participatory Medicine and Declaration
"Participatory Medicine is a cooperative model of health care that encourages and expects active involvement by all connected parties (patients, caregivers, healthcare professionals, etc.) as integral to the full continuum of care. The ‘participatory’ concept may also be applied to fitness, nutrition, mental health, end-of-life care, and all issues broadly related to an individual’s health."
Wednesday, February 10, 2010
news item - court case - Charleston woman names physician, practice in medical negligence case | West Virginia Record
Note: this article does not mention what type of cancer although it references gynecologic oncology
SGO Tumor Board Discussant presentation on Ovarian Cancer Neoadjuvant Chemotherapy by Ignace B. Vergote, MD, PhD, University Hospital Leuven, Leuven Belgium
Note: graphics/statistics
Clinical Presentation - 2/2009 (freely accessible) slide and subsequent discussion presentation on debulking procedures/neoadjuvant vs upfront surgery, maintenance therapies comparing outcomes in European/Central American/Canadian studies etc
Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse — Dr Maurie Markman et al
abstract:
"Purpose: To safely assess new drugs, cancer patients in initial cohorts of phase I oncology studies receive low drug doses. Doses are successively increased until the maximum tolerated dose (MTD) is determined. Because traditional chemotherapy is often more effective near the MTD, ethical concerns have been raised about administration of low drug doses to phase I patients. However, a substantial portion of oncology trials now investigate targeted agents, which may have different dose-response relationships than cytotoxic chemotherapies.......
Finding the Right Dose for Cancer Therapeutics—Can We Do Better? — Clinical Cancer Research
Note: very short abstract as below, but good points (in the absence of the full paper)
Abstract:
"Unlike other diseases, dose-selection for cancer therapeutics is often based on the maximum-tolerated dose in phase 1 studies involving relatively few patients. In this issue of Clinical Cancer Research, Jain and colleagues provide evidence that lower doses may be as effective as maximum-tolerated doses in the treatment of cancer patients."
5th Canadian Conference on Ovarian Cancer Research (Toronto) 2010 + Survivor's Workshop
"This special session for survivors will provide updates on emerging research, as well as information about patient resources. Women and their families will have the opportunity to “Ask the Expert” as well as network with other individuals sharing the same experience. Please watch this space for detailed program updates."
Ovarian Cancer Canada - aka colour me stupid??
Editorial note (mine): colour me stupid, but at last check turquoise was not/is not teal
"With turquoise being the colour of the year, this provides us with the perfect opportunity to continue to create awareness about ovarian cancer, the deadliest of all gynecologic cancers. Celebrate our colour throughout 2010 – wear it often, tell your friends and paint your town teal!"
Endometriosis related to family history of malignancies in the Yale series
Conclusions:
"These data suggest a familial association of endometriosis with ovarian, colon and prostate cancers. This evidence could support the genetics and molecular similarities between endometriosis javascript:void(0)and cancer. Future studies will be important to determine a clear genetic link between endometriosis and cancer."
Abstract/full access: What physicians want to learn about sickness certification: analyses of questionnaire data from 4019 physicians
Conclusions:
"A majority of physicians in most types of clinics/practices, not only primary care, indicated the need for more knowledge and skills in handling sickness certification cases. Increased knowledge and skills are needed in order to protect both the health and equity of patients. However, few physicians stated that they needed more skills in filling out sickness certificates, which contradicts previous findings about such documents being of poor quality and suggests that factors other than mere knowledge and skills are involved."
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study (Paroxetine/Paxil/Seroxat)
CONCLUSION: Paroxetine use during tamoxifen treatment is associated with an increased risk of death from breast cancer, supporting the hypothesis that paroxetine can reduce or abolish the benefit of tamoxifen in women with breast cancer. (trade names Seroxat, Paxil)
Blog: What Reporters Missed at the NIH Colon CA Screening State-of-the-Science Conference By: Gary Schwitzer
(includes commentaries)
"....And it's difficult to understand why this didn't get news coverage. It sure sounded newsworthy to me."
Blog: Preempting End-of-Life Decisions
"I do not want my life to be prolonged if, to a reasonable degree of medical certainty, my situation is hopeless."
"I want my life to be prolonged as long as possible within the limits of generally accepted medical standards, even if this means that I might be kept alive on machines for years."
"Check one. That's one of the places where I'm stalled on making my advance medical directive."
Augmentation of Therapeutic Efficacy in Drug-Resistance - breast and ovarian cancers - C6 (CER) + Paclitaxel
"This study describes a novel mechanism to overcome MDR through a polymer-blend nanoparticle platform that delivers a combination therapy of C6-ceramide (CER), a synthetic analog of an endogenously occurring apoptotic modulator, together with the chemotherapeutic drug paclitaxel (PTX), in a single formulation. ( PTX/CER )
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds -- Grindedal et al. 47 (2): 99 -- Journal of Medical Genetics
Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.
Tuesday, February 09, 2010
Assessment of clinical practices among cancer genetic counselors
Note: refers to time spent by genetic counselors in advising patients
Rate of severe ovarian damage following surgery for endometriomas
CONCLUSIONS: Severe ovarian damage, occurring in gonads operated on for ovarian endometriomas, is not a rare event.
news item: Paxil Blocks Tamoxifen Lowers Survival Odds Against Breast Cancer - Breast Cancer
"Patients taking Paxil and tamoxifen should talk with their doctors about changing their antidepressant, Juurlink said. But he advised against abruptly discontinuing Paxil.
"There is a very real danger to stopping Paxil suddenly. There is a well-described withdrawal syndrome and the risk of depression becoming more severe," he said.
In addition, any transition to another antidepressant should be done gradually over several weeks, he said."
Monday, February 08, 2010
Northwest Biotherapeutics Inc. - press release
"The Company is also conducting a Phase I/II trial with DCVax(R) for recurrent metastatic ovarian cancer."
Marshall Edwards, Inc. Announces Resignation of Christopher Naughton From Board of Directors
Note: the OVATURE ovarian cancer trial results are to be published later this year - Phenoxodiol
Do Canadian patients trust others like them?
"Trust in a “person like yourself” has decreased from 2008 to 2009 (as have most information sources listed in the report), and dropped again in 2010. From the global 2010 Edelman report, 44% of respondents aged between 25-64 years said they would find the information from a person like them to be either ‘very credible’ or ‘extremely credible’ (down from 47% in 2009, and 58% in 2008). That’s a huge drop over the past 3 years!......Another point to keep in mind is that a “person like yourself” is not the same as a “patient like yourself”. "
Sunday, February 07, 2010
2009 A Pan-Canadian Clinical Practice Guideline: Assessment of Psychosocial Health Care Needs of the Adult Cancer Patient
Note:
1) next update is 2014;
2) a quick search reveals that data was:
included for: breast,colorectal,lung,prostate
not included for: ovarian,brain,pancreatic,leukemia,lymphoma
CCAC_Research January 15, 2010 Section 10. ColoMarker
Note/Warning: very graphic images included in this newsletter
Section 10: ColoMarker Tests for Colon Cancer (Dec. 17/09)
Dec 2009: Colorectal Cancer Association of Canada - DNA stool tests for colorectal cancer
DNA stool test A DNA stool test screens stool for DNA mutations, indicating the presence of precancerous polyps or colon cancer"
* Pros: No dietary changes are required before the test. There’s no need to empty the colon ahead of time. Stool sample collection can be done at home.
* Cons: The test currently screens for a limited number of DNA mutations in stool. The test hasn’t been universally accepted as a screening tool for colon cancer. False-negative results are possible.
Search of: ovarian cancer | Adult | received from 01/01/2010 to 02/07/2010 - List Results - ClinicalTrials.gov
Search of: 'ovarian cancer' received from 01/01/2010 to 02/07/2010 - List Results = 11
Does risk-reducing bilateral salpingo-oophorectomy leaved behind residual tube?
Abstract
Objective
Risk-reducing bilateral salpingo-oophorectomy (RRSO) is an effective option for women with BRCA mutations however there is limited information as to how much tubal epithelium remains after RRSO.
Saturday, February 06, 2010
Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Conclusion. Preoperative serum TN is a useful prognostic indicator of advanced stage for patients with OvCa.
Mental health and occupational wellbeing of Australian gynaecologic oncologists
Conclusion:"Australian gynaecologic oncologists experience considerable occupational distress while possessing high levels of personal accomplishment and job satisfaction. To maintain a healthy workforce, it is important to build on existing supports while conducting further research to identify suitable evidence-based strategies for improving the mental health of these surgeons."
Radical hysterectomy during the transition period from traditional to nerve-sparing technique
Conclusions:"Although during the introductory period nerve-sparing technique brings about an improvement in voiding function, it prolongs the total operative time in comparison to traditional radical hysterectomy."
Evaluation of the risk of malignancy index in daily clinical management of adnexal masses
Conclusions
"In our study population, introduction of the RMI would improve the management of adnexal masses, with a higher percentage of ovarian cancer patients that are operated by a gynecologic oncologist. At the same time, referral of patients with non-invasive (benign and borderline) lesions would be reduced."
When ‘never-events’ occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes
Note: 'never-events' is a term used in patient safety (eg. language - near misses, etc)
Conclusions.
"Women with CCC-O have a 2.5-times greater risk of disease related VTE than women with other histologies of epithelial ovarian cancer despite adherence to prophylactic guidelines. Given the high rate of VTE postoperatively as well as with disease recurrence, one should consider indefinite therapeutic anticoagulation in women with CCC-O. The case of CCC-O is one example of the impracticality of payment denial for ‘never-events,’ as VTE arises despite best efforts at prevention."
Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer
Conclusion: Intraperitoneal chemotherapy regimens using carboplatin or cisplatin and dropping day 8 IP paclitaxel have less toxicity and less discontinuation of therapy
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: Final survival results of a SWOG (S0200) phase 3 randomized trial
Conclusion: "Despite a favorable impact of carboplatin and PLD on progression-free survival in this trial, the effect on overall survival is not statistically significant. For currently unknown reasons, administering PLD with carboplatin appears to substantially reduce the incidence of platinum-associated hypersensitivity reactions."
Quality of care in advanced ovarian cancer: The importance of provider specialty.
BACKGROUND: One of the cornerstones of ovarian cancer therapy is cytoreductive surgery, which can be performed by surgeons with different specialty training. We examined whether surgeon specialty impacts quality of life (as proxied by presence of ostomy) and overall survival for women with advanced ovarian cancer.
abstract: Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: The big picture
"We propose that future international cooperation should aim at a uniform pooled analysis of the wealth of ovarian cancer array data already available. This will enhance the power of each separate ovarian cancer study and can lead to promising results."
Protein That Splices And Dices Genes Identified By Scientists
"A novel finding, described Feb. 4 on the Science Express Web site by teams from the National Cancer Institute, The University of Texas Health Science Center at San Antonio and the University of Toronto, offers a clue as to how genes can have what you might call multiple personalities...."
Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: A Multicenter Phase II Trial
Conclusion
The combination of PLD and continuous IFO is a feasible and efficient treatment in patients with relapsed ovarian cancer, especially with TFI between 6 and 12 months. This regimen may represent an alternative to platinum reintroduction and should be evaluated in a randomized trial.Survival after recurrence in early-stage high-risk epithelial ovarian cancer: A Gynecologic Oncology Group study
Abstract
Objective
This study aimed to evaluate the clinical outcome of recurrent early-stage high-risk epithelial ovarian cancer patients.The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: An exploratory analysis of a Gynecologic Oncology Group study
Abstract Objectives A prior clinical trial on early-stage high risk ovarian cancer showed a lower recurrence rate in those treated with six vs. three cycles of chemotherapy. We proposed to identify subsets of patients who may benefit from more cycles of chemotherapy.
abstract: From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer
Note: patients enrolled between January 2006 to December 2007 "Background: The objective of the study was to evaluate completion rates and toxic effects of an i.p. chemotherapy regimen in a cross-section of nonselected patients with ovarian cancer (OC). Conclusions: The i.p. chemotherapy regimen used in a consecutive cohort of patients carries could be completed in only a small percentage of patients. Less toxic regimens with higher acceptability should be considered."
Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study
re: tumour assay testing
"Conclusions: While the small patient numbers in this trial do not permit definitive conclusions, these data fail to provide support for the argument that prospectively obtained in vitro data regarding platinum or paclitaxel resistance will be highly predictive of clinical outcome in advanced ovarian cancer."
Oncogene - Abstract (technical): Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer
Definition: Cadherins - (Calcium dependant adhesion molecules) are a class of type-1 transmembrane proteins. They play important roles in cell adhesion.
Definition: Gonadotropin - hormone secreted by the anterior pituitary gland and placenta; stimulates the gonads and controls reproductive activity. A hormone that stimulates the ovaries (such as to produce estrogen).
"These results identify for the first time cadherin switching and p120ctn signaling as important targets of GnRH function and as novel mediators of invasiveness and tumor progression in ovarian cancer."
Menopausal Hormone Therapy Use and Risk of Invasive Colon Cancer: The California Teachers Study -- American Journal of Epidemiology
" ....perimenopausal or postmenopausal....
Dying at home: community nurses' views on the impact of informal carers on cancer patients' place of death European Journal of Cancer Care
Note: abstract; one of the few articles which challenges mainstream research discussing the issues of dying at home and the wishes of patients/caregiver.
HTML Full Text - Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours
(included ovarian cancer patients in study)
Friday, February 05, 2010
Safe Work Hours, Safe Patients | WakeUpDoctor.org
"Other industries responsible for public safety (e.g., the transportation and nuclear power industries) have been subject to federal regulations that limit the number of hours their employees can work for decades."
Grants.gov - 2010 (research) Ovarian Cancer
Expected Number of Awards: 12
Estimated Total Program Funding: $4,100,000
Description:
NEW for FY10, the OCRP Translational Pilot Award mechanism supports innovative translational research addressing a critical problem or question in ovarian cancer that will accelerate the movement of promising ideas toward clinical applications.
IGRT, SBRT Guidelines Issued By ASTRO, ACR
"The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) have released practice guidelines for image guided radiation therapy (IGRT) and stereotactic body radiation therapy (SBRT) in the February issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO."
Surgical Mesh - Complications Associated with Transvaginal Implantation of Surgical Mesh for the Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse - Notice to Hospitals
Note: warnings on surgical mesh complications exist for other procedures as well (search adverse events reports)
Thursday, February 04, 2010
Cochrane Canada Symposium (includes consumers/patients)
Subject: Cochrane Canada Symposium Workshop: Cochrane Canada 8th Annual Symposium - Evidence in Uncertain Times: Meeting the Challenge Date: 19-20 May 2010, Presymposium: 17-18 May 2010 Location: Ottawa, Ontario, Canada Details: We invite researchers, health policy makers and managers, health professionals, and patients to join the Canadian Cochrane Centre as we discuss Evidence in Uncertain Times at our 8th annual symposium. Abstract submission for workshop, oral and poster presentations is open until 12 February 2010. Early Bird registration ends on 19 March 2010 Email: ccnc.symposium@uottawa.ca Website: www.ccncsymposium.com
Topics – Lack of Appetite and Loss of Weight – Canadian Virtual Hospice
Lack of Appetite and Loss of Weight
Rare ovarian tumours: therapeutic strategies in 2010, national website observatory for rare ovarian cancers and delineation of referent centers-France
Note: ignore the small spelling errors in the article as it was translated from French to English
Peritoneal-based Malignancies and Their Treatment. [Ann Acad Med Singapore. 2010] - PubMed result
Conclusion: It is important to recognise the role of and indications for CRS and HIPEC
MicroRNAs in ovarian carcinomas -- Dahiya and Morin 17 (1): F77 -- Endocrine-Related Cancer
(abstract) FOCUS REVIEW
MicroRNAs in ovarian carcinomas
Neetu Dahiya1 and Patrice J Morin1,2
1 Laboratory of Cellular and Molecular Biology, National Institute on Aging, NIH Biomedical Research Center, 251 Bayview Boulevard, Suite 100, Room 6C228, Baltimore, Maryland 21224, USA
2 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
Phase 1Trial Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer - Full Text View - ClinicalTrials.gov
In Research: Yale Makes Possible Breakthrough in Ovarian Cancer Treatment | NBC Connecticut
"Genetic researchers prevent genes from performing their function, "knocking down" the gene, by inserting small interfering RNA (siRNA) molecules into the cells. The next steps in the team's research will be to examine the effect of siRNA in ovarian cancer samples in the lab, and to test the technique on mice."
EPGM-Munich - Expert Practice in Gynecologic Oncology - free access
There are a number of slide presentations (free full access)
Muir-Torre syndrome-is it really a new syndrome? Am J Dermapathology
Note: that there is an overlap here with Lynch Syndrome
"This syndrome is defined as the coexistence of sebaceous adenomas, sebaceus carcinomas, keratoacanthomas, and pedunculated tumors, some with lobulated structure. The cutaneous involvement (sebaceous gland tumor) is associated with at least a single internal malignancy; mostly colonorectal or genitourinary malignancies."
Medical News: Hidden Dangers of Herbal Meds Reviewed - in Primary Care, Alternative Medicine from MedPage Today
discusses some of the negative interactions
Wednesday, February 03, 2010
Deadline February 28th: Nominations: Becoming a Member
Ideal Candidates for the NCI Director's Consumer Liaison Group:
Ideal candidates must:
1. have first-hand knowledge of the cancer experience;
2. be affiliated with a cancer-related constituency; and
3. possess relevant non-scientific skills and perspectives that will allow them to help improve research outcomes by identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI decisions.
Wait Times For Medical Care: How The US Actually Measures Up - Better Health
Note: ACOR ovarian cancer members - the report will be in the archives - Commonwealth Fund
Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma
Note: technical/abstract
Journal of Chemotherapy 2009 full access: What is the Benefit of 'Avastin' Combined with Chemotherapy in Patients - recurrent Ovarian, Primary ....
Journal of Chemotherapy 2009 full access: What is the Benefit of 'Avastin' Combined with Chemotherapy in Patients - recurrent Ovarian, Primary Peritoneal, Fallopian Tube Cancers.
Note: 64 patients in study; descriptive (stage 1C+); stage 1/11=4 pts; clear cell (2);endometrioid (3); mucinous (2);platinum resistant; side effects....(paper takes time to download)
Cochrane Collaboration Review: Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignancies
Authors' conclusions:
Placement of retroperitoneal tube drains has no benefit in prevention of lymphocyst formation after pelvic lymphadenectomy in patients with gynaecological malignancies. When the pelvic peritoneum is left open, the tube drain placement is associated with a higher risk of short and long-term symptomatic lymphocyst formation.
Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection press release - National Institutes of Health (NIH)
"The team used this approach to screen blood specimens from breast, ovarian and prostate cancer patients....They found distinct abnormal mucin-type O-glycopeptide epitopes (parts of molecules that antibodies will recognize and bind to) that were targeted by autoantibodies in cancer patients — but such antibodies were absent in healthy controls.....Although larger sets of specimens will have to be analyzed to fully appreciate the clinical value of this technology, the preliminary results are very promising.The study was an international collaboration that was funded in part by NCI through the trans-NIH Alliance of Glycobiologists for Detection of Cancer and Cancer Risk."
Stanford's Canary Center strives to find cancer sooner than every before - 2/01/10 - San Francisco News
"Scientists at the Canary Center say their first blood test, developed for ovarian cancer, is about to begin phase one clinical trials at Stanford. The first patient group will be women at high risk for ovarian cancer."
In Research: Magnetic Nanoparticles Latch On, Ferry Cancer Cells Out of Body
includes reference to ovarian cancer
End of LIfe Care in the 21st Century: Advanced Directives in Universal Rights Discourse
....legally binding international convention that would outlaw human rights violations in end-of-life decision-making.
Evidence-Based Medicine Requires Appropriate Clinical Context - re: Deep VeingThrombosis (excerpt)
"What if a patient—after diagnostic tests have been performed and there is no more certainty to obtain—still has a 1 in 100 chance of having venous thromboembolism (VTE)? Should the patient's physician engage the patient in a discussion of the harm and benefit of anticoagulation? What if the chance of VTE was 1 in 20? Or even 1 in 10?"
Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy
Note: includes professional commentaries; Implications for all patients ($$)
Searching for the roots of ovarian cancer | Health & Fitness News - OregonLive.com
"It's very frustrating for patients and for researchers that there hasn't been significant advances in ovarian cancer," says Dr. Tanja Pejovic, a gynecologic oncologist and associate professor at Oregon Health & Science University......Pejovic's group at OHSU is among those seeking to understand the basic biology as a means to zero in on likely markers of early disease. In a study reported in December, the group monitored the action of 69 genes in cells that make up the ovarian surface epithelium. They identified a set of genes that appear to become more active as cells progress from normal to cancerous......"We are still trying to understand early events," she says. But Pejovic remains optimistic."We have to understand early events to the point where it can lead us to markers that circulate in the blood."
Reuters Health Information (2010-02-02): Simple ovarian cysts not linked to cancer in postmenopausal women
"Women with and without simple cysts were at similar risk of invasive ovarian cancer after nearly 8 years of follow-up evaluation, the authors write. Furthermore, traditional ovarian cancer risk factors, such as increasing age, family history of breast or ovarian cancer, nulliparity, and infertility, were not associated with simple cysts. Finally, changes in average CA-125 were not correlated with increases in the number or progression of simple cysts.Thus, Dr. Greenlee and his group conclude, "Simple cysts are not likely cancer precursors or markers of increased risk and can be followed conservatively.""
full free access: A novel germline PALB2 deletion in Polish breast and ovarian cancer patients
Conclusions:
The c.509_510delGA is a novel PALB2 mutation that increases the risk of familial breast cancer. Occurrence of the same PALB2 alteration in seven unrelated women suggests that c.509_510delGA (p.R170fs) is a recurrent mutation for Polish population.
Tuesday, February 02, 2010
Cochrane Symposium - Ottawa May 2010
Upcoming Cochrane Collaboration conference includes seminars for consumers/patients
Fertility-sparing surgery in young women with invasive epithelial ovarian cancer.
Note: this study also discusses tumour rupture/survival; the abstract does not include specific cell types, however, clear cell can be possibly presumed given the research data on Japanese women with clear cell ovarian cancer.
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Note: The response rates in this study either alone or in combination were low. The side effects appear to be understated (abstract).
Monday, February 01, 2010
Drugs A-Z List - A on RxList
This is a useful website for finding a lot of information relating to drugs, including chemotherapies. It includes drug interactions, warnings, generic names, pill identifier, medical dictionary etc. The website has been around for many years.
full free access: from the series - the Art of Oncology : "Pessimism Is No Poison"
"....The fellow asked the oncologist why he was so pessimistic when talking with the patient. Why did he say things to make the patient and her husband cry? Shouldn't he have given the patient more hope? Would it not have been better for the patient to hear this dire news in chunks over the course of several clinic visits? After all, the patient was so young she may just beat the odds....."
PLoS ONE: Risk of Ovarian Cancer and Inherited Variants in Relapse-Associated Genes
"...We previously reported results of tumor mRNA expression studies which suggested that altered expression of a particular set of genes predicted response to chemotherapy among women with advanced-stage high-grade epithelial ovarian cancer.......Conclusions: "Tumor studies can reveal novel genes worthy of follow-up for cancer susceptibility. Here, we found that inherited markers in the gene encoding MSL1, part of a complex that modifies the histone H4, may decrease risk of invasive serous ovarian cancer."
full free access: Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study
Note: the full access to this publication is available for free; professional comments included CONCLUSION: The risk of deep vein thrombosis and pulmonary embolism after surgery is substantially increased in the first 12 postoperative weeks, and varies considerably by type of surgery.
Journal of Experimental & Clinical Cancer Research | Full text | Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research
Note: there is a specific section on ovarian cancer
Background: Viscum album L. extracts (VAE, European mistletoe) are a widely used medicinal plant extract in gynaecological and breast-cancer treatment. Conclusion: VAE shows some positive effects in breast and gynaecological cancer. More research into clinical efficacy is warranted.
Use of CT Scans Linked to Cancer Risk, Studies Say | netReturns | e-Newsletter
"There is considerable disagreement in the scientific community about the validity of these models," notes Rosaleen Parsons, M.D., chair of the department of diagnostic imaging at Fox Chase Cancer Center. "And some scientists believe the radiation dose from these CT scans may not lead to any increased risk of cancer."
In the second study, conducted at the University of California-San Francisco, researchers compared CT scan use at four San Francisco Bay area facilities. They found that the amount of radiation from a CT scan may be up to four times greater than estimated in previous studies. In addition, they noted significant differences among different institutions and, in some instances, within the same institution, when looking at the radiation dose associated with CT scans.
Sunday, January 31, 2010
Editorial: The heterogeneity of epithelial ovarian cancer. Getting it right David M. Gershenson
Editorial
The heterogeneity of epithelial ovarian cancer
Getting it right
David M. Gershenson, MD *
Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
email: David M. Gershenson (DGERSHEN@mdanderson.org)
Abstract
Epithelial ovarian cancer is heterogeneous and comprises 4 major rare subtypes - mucinous, clear cell, low-grade serous, and endometrioid - all distinct from the more common high-grade serous carcinoma. Women with uncommon histotypes should be triaged to separate clinical trials.
Search of: ovarian cancer | Open Studies | Adult - Results by Topic - ClinicalTrials.gov
Search results for Dietary Supplement - ovarian cancer:
Acidophilus 1 study
Arginine 1 study
Calciferol 4 studies
Cholecalciferol 3 studies
Citrate 13 studies
Folate 7 studies
Folic Acid 7 studies
Folinic Acid 8 studies
Orange 1 study
Tea 1 study
Tyrosine 1 study
Vitamin B9 7 studies
Vitamin D3 3 studies
Cancer patients 'must know rights' UK/Macmillan Cancer Centre
"Macmillan Cancer Support said that workers don't realise the Disability Discrimination Act (DDA) also protects cancer patients. A survey for the charity found more than half (53 per cent) of the 1,000 people questioned did not realise the act also applied to cancer patients."
media article: The inherited malignancy of breast cancer (and ovarian cancer)
Note: good article, albeit complicated subject matter - excerpts of important information:
Soy product and isoflavone intake and breast cancer risk defined by hormone receptor status. 2009; Cancer Science
"he association between soy food consumption and breast cancer risk has been inconsistent. A hospital-based case–control study was conducted to assess the relationship between soy food intake and breast cancer risk according to the estrogen receptor (ER) and/or progesterone receptor (PR) status of breast cancer in Chinese women .....The protective effects of soy did not seem to differ by ER and PR breast cancer status."
(abstract) Aberrant DNA methylation in contrast with mutations. 2009; Cancer Science
Note: technical/short abstract
Saturday, January 30, 2010
videos: The Chemotherapy Foundation Symposium
Note: there are some key videos (free to view) from a variety of subjects
Meeting Archives
Chemotherapy Foundation Symposium XXVI
November 4 -8, 2008
Marriott Marquis Hotel , New York , NY
November 4 -8, 2008
Marriott Marquis Hotel , New York , NY
Innovative Cancer Therapy for Tomorrow
Friday, January 29, 2010
2007 Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites
reference: Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 25, No 18S (June 20 Supplement), 2007: 9043
Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites? -- The Oncologist
"Despite the very strong preclinical evidence for an obligatory role of VEGF in the formation of malignant ascites and for a possible therapeutic efficacy of anti-VEGF therapies in the setting of malignant effusions, there are currently no reports from clinical studies addressing this point in cancer patients..........To date, only very few patients with malignant ascites have received i.p. bevacizumab and, therefore, this route of administration as well as this particular patient population need to be examined stringently regarding the safety of the treatment. However, we believe that i.p. application might be the route of choice in this particular setting."
Immunotherapy of Cancer: Key Findings and Commentary on the Third Tegernsee Conference -2009- The Oncologist
*the Oncologist now requires a subscription $$/abstracts available for free
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma -- The Oncologist
*the Oncologist now requires a subscription $$/abstracts available for free
Patient Safety: note the adverse effects
"In the reviewed trial, serious adverse events and National Cancer Institute Common Terminology Criteria for Adverse Events grade
3 adverse events were reported more frequently in
bevacizumab-treated patients (31% versus 19% and 63% versus
47%, respectively). The most common bevacizumab-related
toxicities were bleeding/hemorrhage, hypertension,
proteinuria, and venous or arterial thromboembolic events."
Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside -- The Oncologist
*the Oncologist now requires a subscription $$/abstracts available for free
Preventing Future Cancers by Testing Women With Ovarian Cancer for BRCA Mutations -- University of British Columbia/MD Anderson
"BRCA testing of women with ovarian cancer based on personal/family history of cancer or Ashkenazi Jewish ancestry is a cost-effective strategy to prevent future breast and ovarian cancers among FDRs (first degree relatives). More inclusive testing strategies prevent additional cancer cases but at significant cost."
GenSpera Announces First Cancer Patient Treated With G-202 In Phase I Trial
WARNING: this information is from a media article and gives virtually no information, so cautions. This obviously is not intended to discredit Johns Hopkins/Wisconsin Cancer Center, but the lack of information in the article.
"Patients interested in enrolling in the G-202 trial may contact the University of Wisconsin Carbone Cancer Center Connect line at (800) 622-8922. Patients who want to be evaluated for eligibility for this study at Johns Hopkins should call 410-955-8964, option #2. "
Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes
Note: highly technical paper comparing serous, clear cell and endometrioid ovarian cancer cells type/endometriosis/Interleukins (in research)
Patient Advocate Foundation :: 1-800-532-5274
help for solving insurance and access problems (U.S.):
Patient Advocate Foundation :: 1-800-532-5274
Thursday, January 28, 2010
media article: Plant-based flavonoid may cut ovarian cancer risk (Apigenin)
language issues: borderline - significant ??
"women reporting the highest apigenin intake had a "borderline significant decrease" in ovarian cancer risk"
Time to end pelvic exams done without consent - The Globe and Mail
This article by Andre Picard of the Globe and Mail is a regurgitated column previously noted media columns. Interestingly enough the SGOC has an 'award' for columnists at the moment so it is highly suspect in its timing.
However, included are comments from both public and healthcare individuals.
Illumina to Complete Analysis of Ovarian Cancer - Sequencing - Genome Web
"The original plan was to analyze 25 ovarian and 25 gastric tumor/normal pairs by the end of 2009 using the company's Genome Analyzer, including whole-genome sequencing to at least 30-fold coverage, mRNA-seq, methylation sequencing, and chip genotyping. That timeline got delayed somewhat, and the company now expects to finish the ovarian tumors by the end of March and move into a validation phase, and then tackle the gastric cancer samples.
The delay was largely due to a longer-than-expected process of acquiring and qualifying the samples, Heath explained. For the ovarian cancer project, for example, he said the company was looking for stage I or II samples with a tumor content of at least 70 percent from non-smokers who did not have mutations in the BRCA 1 or 2 genes. He also said that the type of consent required for whole-genome sequencing is "quite a bit different from what is normally consented" and required the company, in some instances, to go back and ask for additional consent."
Contrast-enhanced ultrasound in the detection and characterization of liver tumors
"Contrast-enhanced ultrasound (CEUS) has unique advantages over contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) in the characterization of hepatic tumors."
Now's the time to find biomarkers on purpose -- Annals of Oncology
"Studies need to be conducted to determine the optimal design for using genome-wide profiling to identify putative biomarkers of drug response. To date, most biomarkers of drug response identified through genome-wide profiling have occurred through retrospective analysis of available tissue. To really progress this field, realistic planning for biomarker discovery and validation in clinical trials needs to be conducted. We, as clinical scientists, need to progress from only using convenient clinical cohorts to identify biomarkers to actually planning and following through with prospective clinical trials whose aims are to discover and/or validate putative biomarkers of drug response. To initiate a study without a realistic plan for discovery and validation reflects a lack of serious desire to find robust clinical predictors..... Until this becomes more commonplace, the genomic revolution will be focused on manuscript generation and investigator career development, leaving the benefit to patients nothing more than an unrealized dream."
Patient Participation: Current Knowledge and Applicability to Patient Safety — Mayo Clinic Proceedings
"...Patient-related factors, such as acceptance of the new patient role, lack of medical knowledge, lack of confidence, comorbidity, and various sociodemographic parameters, all affect willingness to participate in the health care process. Among health care workers, the acceptance and promotion of patient participation are influenced by other issues, including the desire to maintain control, lack of time, personal beliefs, type of illness, and training in patient-caregiver relationships. Social status, specialty, ethnic origin, and the stakes involved also influence patient and health care worker acceptance.
Cancer Causes and Controls: abstract - Microsatellite instability and survival in rectal cancer (Lynch Syndrome)
"Abstract
Objective High levels of microsatellite instability (MSI-H) have been associated in many studies with improved prognosis in colon cancer. Very few studies have evaluated the effect of MSI-H on rectal cancer survival. We assessed MSI-H and other genetic and epigenetic changes on survival of 990 individuals diagnosed with first primary rectal cancer.
Conclusion The genetic and epigenetic characteristics of MSI-H rectal cancers suggest that they are enriched for Lynch-associated tumors; adverse prognosis associated with MSI-H in these tumors may reflect the relatively high frequency of Lynch-associated cancers and/or the effect of radiation or chemotherapy on Lynch-associated rectal cancers or MSI tumors in general."
Women's decision-making needs related to treatment for recurrent ovarian cancer: a pilot study
"abstract:
The purpose of this pilot study was to describe the decision-making needs of women with ovarian cancer related to treatment of recurrent disease. ..... CONCLUSIONS: The findings provide some beginning direction for an inter-professional decision support approach, as well as implications for future research.
Email Guidelines for Patients (Patient Handout)
About these guidelines
Adopting appropriate email practices with patients is an important step
to safeguarding the integrity of the doctor-patient relationship and
maintaining the confidentiality of sensitive patient information.
The email guidelines that you are about to generate will outline when, why and how your patients may use email to contact you.
These guidelines can be:
- printed and used as a patient handout
- used as a patient consent form
- used as a statement of best practices for you and your staff
- saved on your computer
- downloaded from your practice website
A Revision Of The EU Clinical Trials Directive Supported By European Cancer Organization
"Certain groups of patients have been particularly hard hit: children, patients with rare cancers, patients who would profit greatly from international trials that optimise already existing treatments and which, therefore, do not find commercial sponsorship, and elderly patients with other health problems, including secondary cancers due to earlier treatments."
Wednesday, January 27, 2010
2009 Expert Perspectives on Challenges, Controversies, and Opportunities in Ovarian Cancer Therapy: The Present and the Future | PeerView Press
(free) viewing:
Includes: Dr's Markman, Armstrong & Coleman
Topics:
- Expert Perspectives on Challenges, Controversies, and Opportunities in Ovarian Cancer Therapy: The Present and the Future
- Taking Stock of the Current Research: Which New Therapies Are Showing Promise in Ovarian Cancer?
- Audio - Q&A Lightning Round: Expert Opinions on Unanswered Questions and Controversies in Ovarian Cancer
quick search - ovarian cancer - Clinical Research as at 1/28/2010 9:51 pm EST
There are 5 clinical trials at NIH that match your search criteria
Cancer by type/disease: Ovarian Cancer
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer Clinical, Genetic, Behavioral, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 (KU-0059436) Combined With Carboplatin in Breast and Ovarian Cancer in BRCA 1/2 Mutation Carriers, Familial Breast and Ovarian Cancer, and Sporadic Triple Negative Breast Cancer and Ovarian Cancer
A Phase I, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Refractory Solid Tumors Associated With EphA2 Expression
A Phase I Study of Dasatinib in Combination With Bevacizumab in Advanced Solid Tumors
Healthcare-Associated Infection: Not on My Watch - Kimberly-Clark Health Care
"When someone develops an infection at a hospital or other patient care facility that they did not have prior to treatment, this is referred to as a healthcare-associated (sometimes hospital-acquired) infection (HAI).
Healthcare-associated infections (HAIs) are a global crisis affecting both patients and healthcare workers.
According to the World Health Organization (WHO), at any point in time, 1.4 million people worldwide suffer from infections acquired in hospitals."
A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer- Molecular Endocrinology
"Our experiments have revealed strong candidate miRNAs and their target genes that may contribute to the pathogenesis of clear cell ovarian cancer, thereby highlighting alternative therapeutic strategies....."
Columns - Focus on Policy - Outliers: The Story of Success
"Gladwell asks why it is so difficult to acknowledge the fact that each of us comes from a culture with its own distinctive mix of strengths and weaknesses, tendencies, and predispositions. "Who we are cannot be separated from where we are from -- and when we ignore that fact, planes crash."
And patients die."
Why doctors' stories matter
"...As I read the winning stories, I had a fantasy, which is probably not a good idea to apply literally, but it’s useful as what philosophers would call a thought experiment. My fantasy was that in a doctor’s waiting room, instead of old magazines and public health brochures, patients might pick up stories that the doctor had written—stories not unlike these winning stories. And maybe patients would then bring in their stories and leave copies of those on the rack next to the doctor’s stories. That would open the silent world on both sides."
Does computer use in patient-physician encounters influence patient satisfaction?
EDITOR’S KEY POINTS
- Patient-physician communication is central to every physician’s practice and to patient satisfaction. Physicians have been concerned that the introduction of computers into patient consultations will lead to a breakdown of communication.
- This study sought to examine patients’ opinions about the effects of computer use on patient-physician interaction and on their satisfaction with their visits.
- Results of this study suggest that concerns about computer use negatively affecting patient-physician relationships and patient satisfaction are largely unfounded. Most patients had no preference for whether computers were used or not, and computer use actually seemed to have a positive effect on overall satisfaction. Other studies have shown that patients’ main concerns about computer use have to do with privacy, but in this study only 3.4% of respondents were concerned about a "negative" or "very negative" effect on privacy.
Interview: The Health 2.0 Blog: ACOR, Health 2.0 in the US & Europe: Gilles Frydman tells all
"Gilles Frydman is one of the leading ePatients. He started and runs ACOR (Association of Cancer Online Resources) and has discussed the role of engaged patients with rare diseases at the last few Health 2.0 Conferences."
Inherited Determinants of Ovarian Cancer Survival
"Conclusion: An extensive multiple-pathway assessment found evidence that inherited differences may play a role in outcome of ovarian cancer patients, particularly in genes within the angiogenesis and inflammation pathways. Our work supports efforts to target such mediators for therapeutic gain."
Tuesday, January 26, 2010
NCI clincial trial: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi... - Full Text View - ClinicalTrials.gov
Drug: VELCADE, PS-341 (Bortezomib, NSC #681239) Drug: ZACTIMA (Vandetanib) (ZD6474) Phase I Phase II
audio available: The latest in cancer research | Minnesota Public Radio NewsQ
Forty years into the war on cancer, the death rate for many cancers has not changed significantly. Scientists say a new approach is needed. Midmorning talks with two cancer researchers about the latest and most promising research.
Moral angst for surgical residents: a qualitative ... [Am J Surg. 2010] - PubMed result
"BACKGROUND: The ethical dilemmas that residents experience throughout their training have not been explored qualitatively from surgical residents' perspectives.
METHODS: Grounded theory methodology was used. All University of Toronto surgical, otolaryngology, and obstetrics and gynecology residents were invited to participate.Twenty-eight face-to-face interviews were conducted. Interviews were transcribed and analyzed by 3 reviewers.
RESULTS: Five encompassing themes emerged: (1) residents prefer operating with another resident while the staff watches; (2) residents felt that patients were rarely well informed about their role; (3) residents develop good relationships with patients; (4) residents felt ethically obliged to disclose intraoperative errors; and (5) residents experience ethical distress in certain teaching circumstances.
CONCLUSIONS: Residents encounter ethical dilemmas leading to moral angst during their surgical training and need to feel safe to discuss these openly. Staff and residents should work together to establish optimal communication and teaching situations."
Editorial : Measuing performance is essential to patient-centred care
"A health care system should, first and foremost, be organized to meet the needs of patients rather than the needs of institutions and providers. More often than not, however, the needs of institutions and health providers come first. How often do we see patients repeatedly
return to clinics on different days for poorly coordinated visits for diagnostic tests and follow-up with their physician?..."
Evidence Updates: Impact of two supportive care interventions on anxiety, depression, quality of life, and unmet needs in patients (advanced cancer)
Evidence Updates: Impact of two supportive care interventions on anxiety, depression, quality of life, and unmet needs in patients
Girgis A, Breen S, Stacey F, et al. Impact of two supportive care interventions on anxiety, depression, quality of life, and unmet needs in patients with nonlocalized breast and colorectal cancers. J Clin Oncol. 2009 Dec 20;27(36):6180-90. Epub 2009 Nov 16. PMID: 19917842 (Original)
DISCIPLINE RELEVANCE TO PRACTICE IS THIS NEWS?
Oncology - Breast 3 / 7 3 / 7
Oncology - Gastrointestinal 4 / 7 4 / 7
Oncology - Palliative and Supportive Care 6 / 7 6 / 7
Abstract PURPOSE: Patients with cancer experience considerable symptom burden, psychological morbidity, and unmet psychosocial needs. Research suggests that feedback of patient-reported outcomes to clinicians or caseworkers, alongside management strategies, may result in improved patient functioning. Two intervention models were developed to test this effect in a randomized, controlled trial against usual care (UC): a telephone caseworker (TCW) model and an oncologist/general practitioner (O/GP) model. Primary end points included anxiety, depression, physical/emotional functioning, and unmet supportive care needs.
PATIENTS AND METHODS: Participants with nonlocalized breast or colorectal cancers were surveyed by computer-assisted telephone interview (CATI) at three time points: baseline, 3 months, and 6 months. Data collected from participant CATIs in the supportive care models were used to generate feedback to either each participant`s designated TCW, or their nominated O/GPs. Data obtained from participants in the UC model were used only to assess the impact of supportive care models. In total, 356 participants consented to study participation, completed the baseline CATI, and were randomly assigned to the UC, TCW, or O/GP groups.
RESULTS: No overall intervention effect was observed. Physical functioning was significantly improved at the third CATI for participants in the TCW model (P = .01), and there was a trend toward fewer participants with unmet needs (P = .07). TCW group participants also were more likely to have the following: identified issues of need discussed (P < .0001); referrals made (P < .0001); and strong agreement that the intervention improved communication with their health care team (P = .0005).
CONCLUSION: The TCW model holds some promise; however, additional work in at-risk populations is required before we recommend implementation.
Monday, January 25, 2010
full free access: Use of a surgical safety checklist to reduce morbidity and mortality
Note: the use of surgical site checklists stemmed from WHO's Patient Safety group/s.
Cancer Recurrence Fears - MD Anderson Cancer Center
Clinical Trials Matching Service - Ovarian Cancer National Alliance
press release: Women's College Hospital (Toronto) offers Jewish women genetic screening for breast cancer
“Our study identified two major concerns with current breast cancer screening guidelines,” says Dr. Kelly Metcalfe, adjunct scientist at the Women’s College Research Institute and associate professor at the University of Toronto. “The first is that over half of the women we identified with a mutation would never have known that they were at an increased risk of cancer because they were not eligible for genetic testing outside of this study. The second concern was that although 45 per cent of the women with mutations were eligible for genetic testing based on their family history of cancer, none were referred by their health-care provider for screening. "
Two Combination Treatment Regimens Added to Updated NCCN Guidelines for Ovarian Cancer - media item
NCCN updates their guidelines annually - the guidelines on a variety of subjects (cancers/genetics etc) can be found at: http://www.nccn.org
Access requires registration but is free. There is a specific area for the genetics of breast/ovarian but to find genetics relating to Lynch Syndrome you need to go to the colorectal cancer section.
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors - Full Text View - ClinicalTrials.gov
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors - Full Text View - ClinicalTrials.gov:
"This study has been completed.
First Received: April 23, 2007 Last Updated: September 23, 2009
Sponsor: Poniard Pharmaceuticals
Information provided by: Poniard Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00465725"
Pharma press release: re Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
"Our ultimate goal is to secure a strategic partnership to support further development of picoplatin in CRC and other solid tumor indications, including prostate and ovarian cancers.'"
article: (Focused Microwave Thermotherapy) breast cancer therapy reduces mastectomies, saves breast
"In theory, Dooley said the technique could be used on any organ that could be "held relatively still." Scientists are now working to integrate heat-sensitive nanotechnology that would more precisely target cancer cells. They also plan to study a byproduct of the rapid disintegration of the tumor – a boosted immune system."
Sunday, January 24, 2010
Green Tea May Have Cancer Benefit - in Meeting Coverage, AACR-IASLC 2010 conference
"Experimental studies have suggested that one mechanism for chemoprevention with green tea may be its impact on insulin-like growth factors."
Search of: Open Studies | Interventional Studies | solid tumors | Adult | Phase II III IV - List Results - ClinicalTrials.gov
search results = 137 clinical trials
Saturday, January 23, 2010
full free access: Early-onset breast cancer in a Lebanese family with Lynch syndrome due to MSH2 gene mutation
"Background: There are still controversies about the integration of breast cancer as a part of the disease spectrum in Lynch syndrome."
full free access: Type D personality in the general population: a systematic review of health status, mechanisms of disease, and work-related problems
"Type D personality in the general population: a systematic review of health status, mechanisms of disease, and work-related problems."
Jan 23, 2009: Authors' Reply: Dose-dense paclitaxel for advanced ovarian cancer – Authors' reply : The Lancet
Authors' explanation to Commentaries 1 & 2
Jan 23, 2009: Commentary (1 of 2): Dose-dense paclitaxel for advanced ovarian cancer : The Lancet
Note: may require registration (free):
updated 2010 - MSH2 (one of the Lynch Syndrome genes)
- "People with mutations in the MSH2
gene have an increased risk of developing several other types of cancer (colorectal),
including cancers of the endometrium (lining of the uterus), ovary,
stomach, small intestine, liver, gallbladder duct, upper urinary tract,
brain, and skin.
Some mutations in the MSH2 gene increase the likelihood of several uncommon skin tumors occurring in addition to colorectal cancer, a combination called Muir-Torre syndrome. These rare skin tumors include sebaceous adenomas and carcinomas, which occur in skin glands (sebaceous glands) that produce an oily substance called sebum. Multiple, rapidly growing skin tumors called keratoacanthomas may also occur, usually on sun-exposed areas.
media item: Father's long crusade for answers
Note: "In 2006, a respected cancer research charity started losing donors when it was mistaken for the CCRG following the W5 program."
Understanding the problem of inadequately staging of early ovarian cancer (subanalysis of ACTION trial)
CONCLUSIONS: Even in a randomised trial in which comprehensive surgical staging was strongly advised in the study protocol the majority of patients (66%) were incompletely staged. Factors relating to a lack of surgical skills attributed most to the number of incompletely staged patients, but insufficient knowledge of the tumour behaviour and routes of spread of ovarian cancer also contributed substantially to this problem. Multicentre trials recruiting patients from many institutes with small volume contribution to the study, run the risk of inadequate adherence to the study protocol.
Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey): Findings in Surgical Patients
Note: study of data from 2004
"Use of prophylaxis varied according to major surgery type from 86.0% for orthopedic surgery to 53.8% in urologic/gynecologic...." "Conclusions: The majority of surgical patients are at high-risk for VTE. Despite long-standing recognition of the high-risk for VTE in surgical patients, thromboprophylaxis remains underutilized."
March 1, 2010 abstract: Conundrums in screening for cancer
Mini Review
Conundrums in screening for cancer
|
| Anthony
B. Miller * |
| Dalla
Lana School of Public Health, University of Toronto, ON, Canada |
| email:
Anthony B. Miller (ab.miller@sympatico.ca) |
This article is based upon the Joint International Journal of Cancer and Meyenburg-Stiftung Lectureship, delivered at Deutsches Krebsforschungszentrum, February 18, 2009.
| Keywords |
| screening
for cancer • breast cancer • cervix cancer • prostate cancer |
| Abstract |
| Screening for cancer has to be
carefully organized for maximum effectiveness, and introduced in full
understanding of the natural history of the disease. There are major
potential harms as well as benefits from screening. The current state of
art for breast, cervix and prostate cancer screening is reviewed, only
for breast and cervix are policies of screening in the population
justified. |
Friday, January 22, 2010
Neoadjuvant Bevacizumab May Increase Serious Surgical Complications - OncologySTAT
Note: free access (sign up):
Neoadjuvant_Bevacizumab_May Increase Serious Surgical Complications
media article: Neoadjuvant Bevacizumab May Increase Serious Surgical Complications
"Most complications started in the immediate postoperative period, stuttered along, then worsened weeks later when bevacizumab was restarted, according to Dr. Golshan." "This observation caused one audience member to quip, “Perhaps these wounds, even though they may appear to be healed, should receive more respect and less bevacizumab.”"
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer
"METHODS:: Patients with stage III/IV EOC received cyclophosphamide 750 mg/m(2), followed by a 24-hour infusion of paclitaxel 250 mg/m(2) and cisplatin 75 mg/m(2) on Day 2. Filgrastim began on Day 3 at 10 mug/kg daily for 9 days. Patients received 6 cycles of all drugs." CONCLUSIONS:: The studied regimen yielded a high response rate and encouraging overall survival."
Vermillion Emerges From Bankruptcy -- FREMONT, Calif., Jan. 22 /PRNewswire-FirstCall/ --
"This is a great day for all of our stakeholders as well as women who will benefit from OVA1,' said Gail Page, executive chair of Vermillion. 'We are in a position to resume development of our other programs in ovarian cancer and peripheral arterial disease,' she added."
full free access: Progress in Cancer Care: A Rational Call To Do Better - CA: A Cancer Journal for Clinicians
Editorial by incoming American Cancer Society President - Dr Alan G. Thorson
Study Finds Omission of Axillary Lymph Node Dissection Safe for Patients with Sentinel Node Micrometastases (early stage breast cancer)
full free access: link: http://caonline.amcancersoc.org/cgi/reprint/60/1/2.pdf
BRCA1 185delAG mutant protein, BRAt, up-regulates Maspin in ovarian epithelial cells
"Consequently, understanding early genotypic and phenotypic changes in the context of high risk disease may provide a better understanding of the mechanism of mutation-associated ovarian cancer and provide new targets for therapeutic intervention."
Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study
"Therapy consisted of low-dose subcutaneous IL-2 and oral RA, administered on intermittent schedules for up to 5 years."
Trial design for evaluation of novel targeted therapies
"Conclusions:Alternatives to traditional phase II trial design including alternative end points, randomized designs, biomarkers, and imaging tools should allow ineffective agents to be discarded and promising agents to undergo further investigation."
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma
"Conclusion: Gefitinib, administered in combination with paclitaxel and carboplatin, provides a good clinical response but associated with an increased risk of hematologic disorders."
Nurses oppose the Ontario government's physician assistant role citing inadequate education, concerns over patient safety and unnecessary cost
Note: the RNAO also made the same statement regarding pharmacists (2009)
Toronto, January 22, 2010
"Members of the public will not be well served if the provincial government pursues a plan to allow physician assistants (PAs) to work in hospitals, family health teams, community health centres, and family physician offices. The board of directors of the Registered Nurses' Association of Ontario (RNAO) has unanimously endorsed a position statement, which raises serious questions about the level of education and regulatory oversight physician assistants have and how these could jeopardize patients..."
abstract: Association of Skeletal Muscle Wasting With Treatment With Sorafenib
Note: this study is not specific to ovarian cancer but may be of interest for those deciding on Sorafenib:
Risk factors for reproductive and breast cancers among older lesbians.
Note: the term 'older' in the study was >40 yrs
Cochrane Collaboration review: Antigen-specific active immunotherapy for ovarian cancer
"AUTHORS' CONCLUSIONS: We conclude that despite promising immunological responses no clinically effective antigen-specific active immunotherapy is yet available for ovarian cancer. Furthermore, the adoption of guidelines to ensure uniformity in trial conduct, response definitions and trial reporting is recommended to improve quality and comparability of immunotherapy trials."
Cochrane Collaboration Review: Management of drainage for malignant ascites in gynecologic cancer
"AUTHORS' CONCLUSIONS: Since no relevant studies were identified, we are unable to make recommendations regarding the management of drains for malignant ascites in women with gynaecological cancer. Large, multi-centre RCTs are required to evaluate the efficacy and safety of the management of ascitic drains when in situ and their impact on QOL."
Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock
"The OVATURE trial is a major multi-center international Phase III clinical trial of orally-administered investigational drug phenoxodiol in combination with carboplatin in women with advanced ovarian cancer resistant or refractory to platinum-based drugs, to determine its safety and effectiveness when used in combination with carboplatin.......The Company expects the final analysis will be performed strictly according to the protocol and now is expected to be completed in the second quarter of 2010"
Search of: Open Studies | Interventional Studies | ovarian cancer | Adult | received from 01/01/2010 to 01/22/2010
Results = 3 (new interventional studies since Jan 1/10)
The cost-effectiveness of genetic testing strategies for Lynch Syndrome among newly diagnosed patients with colorectal cancer
MRI, CT, and PET/CT for Ovarian Cancer Detection and Adnexal Lesion Characterization
"CONCLUSION. The goal of imaging in ovarian cancer detection is to expeditiously distinguish benign adnexal lesions from those requiring further pathologic evaluation for malignancy. For lesions indeterminate on ultrasound, MRI increases the specificity of imaging evaluation, thus decreasing benign resections. CT is useful in diagnosis and treatment planning of advanced cancer. Although 18F-FDG-avid ovarian lesions in postmenopausal women are considered suspicious for malignancy, PET/CT is not recommended for primary cancer detection because of high false-positive rates."
MRI of Endometriotic Cysts in Association With Ovarian Carcinoma
Risk Assessment and Genetic Testing for Ovarian Cancer
abstract: Current Update on Borderline Ovarian Neoplasms
CONCLUSION. Borderline tumors are considered to be precursors of low-grade ovarian cancers. Accurate diagnosis and staging facilitate optimal patient management particularly in patients desiring to preserve fertility.
MRI in the planning of initial lumpectomy for invasive breast carcinoma: effect on ipsilateral breast tumor recurrence after breast conserving therapy
CONCLUSION: MRI evaluation of invasive carcinoma in the planning of initial lumpectomies was not associated with improved local outcomes after BCS (breast conserving surgery) with RT in this cohort of patients.
Thursday, January 21, 2010
now accepting applications: Genetic Alliance
"We are now accepting applications for the Advocates Partnership Program at the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting March 24-28 in Albuquerque, New Mexico."
ACOR - Association of Online Cancer Resources - Home Page
ACOR.org delivered 1,819,859 individual emails across the globe last week.
Omega-3 Fatty Acids for Neuropathic Pain: Case Series : The Clinical Journal of Pain
abstract/study of 5 patients
Jan 2009 full free access - Development of PARP inhibitors in oncology; Expert Opinion on Investigational Drugs + Expert Opinion
Note: highly technical but worth reviewing (BRCAness, sporadic, specific therapies (combination/single agent/+radiotherapy), those in clinical studies (Table 1),
differing cancers etc
Wednesday, January 20, 2010
now acceptng applications - Director's Consumer Liaison Group (U.S.)
The DCLG indentifies and responds to issues and challenges facing the Institute at the request of the Director. The DCLG provides relevant, non-scientific skills and perspectives in order to improve research outcomes by identifying new approaches, promoting innovation, recognizing unforeseen risks or barriers, and identifying unintended consequences that could result from NCI decisions.
full free access: Identifying the barriers to conducting outcomes research in integrative health care clinic settings
Conclusions
"..... as IHC clinics are often complex systems, a whole systems approach to research should be used taking into account the multidimensional and complex nature of such treatment systems so that the results are useful and reflect real life."
Dec 2009 article: Influenza Vaccination in Immune Compromised Persons: Practical Advice for Oncologists - OncologySTAT
Note: if you are unable to view the full article then you need to register (it's free)
abstract: Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside -- The Oncologist
"Recent and continuing developments in high-throughput and multiplexed assay platforms as well as in disciplines such as bioinformatics and biostatistics will surely shape the future of clinical trials. Application of novel techniques in a comprehensive approach, revealing the interrelations among targets and the mechanisms of action underlying cancer (systems biology), may lead to comprehensive diagnostic tools (systems pathology) and specific combinations of drugs (cocktails of monoclonal antibodies, RNA therapeutics, or others) in what has been called the actualization of personalized medicine. We know that momentum in the era of targeted therapy will continue to accelerate, bringing new hope to our patients
with cancer and their families"
Abstract/free full access: High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
define: deleterious = harmful
Note: genetic modifying factors of penetrance = factors which result in lower or high risks of cancer
The quality of dying and death: a systematic review of measures-- Palliative Medicine
These are important issues for us as patients/caregivers:
"Less than half were based on an explicit definition of quality of dying and death and even fewer relied on a conceptual model that incorporated multidimensionality and subjective determination.The specified duration of the dying and death phase ranged from the last months to hours of life."
Tuesday, January 19, 2010
Pharma Pipeline News: Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer
Note: conference reporting news item
Cooking with anti cancer herbs and spices better than some medicines
Submitted by Kathleen Blanchard RN- Jan 19th, 2010
Quick Poll - question
Note: The quick poll is anonymous, so for the person who answered 'other' please email me - you can do this direct from the blog, if you wish. Thanks! Sandi
Jan 19, 2009: I’m a Cancer Patient. Should I Ask About PARP Inhibitors? - Health Advice Deborah K. Armstrong
Health Advice
Q. I’m a Cancer Patient. Should I Ask About PARP Inhibitors?
By Deborah K. Armstrong, M.D.
submit your application between March 15-22nd, 2010 - ASCO Patient Advocate Scholarship Program
pdf file - application/criteria
abstract: Safety and efficacy results of the advanced renal cell carcinoma Sorafenib expanded access program in North America
Note: while this is not specific to ovarian cancer knowing the side effects which patients experienced may be helpful
abstract: Clinicopathological features of 67 cases of endometriosis-associated epithelial ovarian carcinoma (China)
"CONCLUSION: Patients of endometriosis-associated epithelial ovarian carcinoma, especially patients with tumors arising from endometriosis, were found to be younger, having a significant lower stage and a better survival, and were mostly diagnosed with the subtype of clear-cell."
abstract: Understanding the support needs of patients accessing test results online. PHRs offer great promise, but support issues must be addressed to
Understanding the support needs of patients accessing test results online. PHRs offer great promise, but support issues must be addressed to ensure appropriate access.
abstract: Phase II biomarker trial of a multimarker diagnostic for ovarian cancer-Australia
CA-125; C-reactive protein (CRP); serum amyloid A (SAA); interleukin 6 (IL-6); and interleukin 8 (IL-8)
"CONCLUSIONS: The use of a panel of plasma biomarkers for the identification of women with ovarian cancer delivers a significant increase in diagnostic performance when compared to the performance of CA-125 alone."
Consistency of self-reported first-degree family history of cancer in a population-based study - Brazil
"The prevalence of cancer history in an FDR (first degree relative) was similar to previous reports in other populations. Consistency and reliability of the self-reported information was high, regardless of educational level."
full free access: Targeting the EGF Receptor for Ovarian Cancer Therapy
Note: numerous different treatments are discussed
News: Docs Feel Stress When Patients Can't Make Own Decisions - survey of Chicago physicians
"In only 10% of cases was a living will involved -- and in fully 35% of cases, the physician did not know if there was a living will or not."
2010 full free access: The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian c
( highly technical )The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer
Monday, January 18, 2010
The C.A.M. Report » Blog
Note: This is a huge site with a vast amount of information including institutional based research etc.
National Center for Complimentary and Alternative Medicine
searchable database: eg. green tea oil, fish oil....
abstract (in research) HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in FT
"Our findings of immunoreactivity for HMGA2 may lead to a novel, useful biomarker to complement p53 in the detection of early-stage serous carcinoma."
media item: In Research: OMRF identifies new method that may improve treatment of ovarian cancers
Who is OMRF?
"Founded in 1946, OMRF is one of the nation’s oldest and most respected nonprofit biomedical research institutes. Located in Oklahoma City, OMRF fosters a worldwide reputation for excellence by following an innovative cross-disciplinary approach to medical research."
Breaking down the breakthrough claims - Blog
Note: this one was all over the news this past week: partial excerpt: "A new drug called dabigatran prevents more strokes with less bleeding than warfarin." Dr. Atlas says: "Dabigatran may be a game changer, but there is one thing the story didn't mention. The group that got Dabigatran had more heart attacks than those who got coumadin. Oops! This could be the real game changer from the FDA's perspective. Note it's still under review there."
abstract: The treatment of menopausal symptoms by traditional East Asian medicines: Review and perspectives
Note: abstract provides very limited information
AMA news: Participatory medicine: A high-tech alliance with patients
"At its most basic level, participatory medicine means shared decision-making and deep patient engagement. Because of the rise in technology use -- as well as an increase in out-of-pocket health care expenses -- this has gone well beyond the traditional tell-me-where-it-hurts conversation between patient and doctor in the exam room....Physicians "are afraid this is something that will cost them time and money, and it will create arguments with patients," Dr. Greene said."
abstract: Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors (1994–2003)
"The prognostic impact of BMI on survival was only noted for underweight patients with serous tumors."
Sunday, January 17, 2010
abstract: Pharmacogenomics of taxane/platinum therapy in ovarian cancer
epigentics: The study of heritable changes in gene function that occur without a change in the DNA sequence
"CONCLUSIONS: Other mechanisms of variability, including epigenetic control of gene expression and copy number variation, may play important roles. In addition, nongenetic influences such as concurrent medications, and physiological and environmental factors could also affect individual responses to taxane and platinum therapy."
August 2009: Safety of (Avastin) Bevacizumab in Advanced Ovarian and Müllerian Cancers: A Review: Bevacizumab and Ovarian Cancer
"To date, several investigators (Table 1) have explored bevacizumab as a single agent or in combination with metronomic chemotherapy in the management of advanced ovarian cancer. All studies to date with bevacizumab as a single agent or in combination with chemotherapy have shown promising responses. The concern is centered on whether the benefit of this therapeutic agent outweighs its potential toxicity."
Clinical Trial: How Our Immune System Can Help Fight Cancer
Note: not yet recruiting for patients - An interesting study bringing together genetics and immune system. Location: New York, U.S.A.
Clinical Trials Search of: Open Studies ovarian cancer Adult- new studies received from 12/01/2009 to 01/17/2010
13 new studies shown (non specific)
Dr Dizon's blog: The Women's Cancer Blog
"Dr. Dizon is a medical oncologist specializing in women's cancers. He takes care of both breast and gynecologic cancers and has interests in new treatments, survivorship, and sexuality, and is Director of Medical Oncology at the Program in Women's Oncology at Women and Infants hospital of Rhode Island. He is also an Assistant Professor of Obstetrics-Gynecology and Internal Medicine at Alpert Medical School of Brown University."
Search of: Open Studies "ovarian cancer"
as at: January 17th, 2010 6:26 pm search results = 447 studies (general non specific search) - all types of studies, all phases
free full access: JAMA -- Funding of US Biomedical Research, 2003-2008, January 13, 2010, Dorsey et al. 303 (2): 137
Note: charts for quick overviews
full free access April 2009: Repertoire of microRNAs in Epithelial Ovarian Cancer
"...Small RNA cDNA libraries were constructed from RNA sample pools....and epithelial ovarian cancer specimens of serous, clear cell and endometrioid histologies....This report expands the body of miRNAs known to be expressed in epithelial ovarian cancer and provides a useful resource for future studies of the role of miRNAs in the pathogenesis and early detection of ovarian cancer."
Cancer Blood Tests
"...The team made the discovery partly by accident. They were studying short pieces of RNA called micro RNAs in human tissue samples. These tiny pieces of RNA, discovered only a few years ago, play a big role in regulating genes, and are now known to be altered in cancer..... In a large majority of the cases, just by measuring the amount of micro RNA in the blood, we could tell who had cancer and who didn’t,” Tewari says."
PBS: Genetic Genealogy on Faces of America - airing February-March 2010
Eva Longoria, Meryl Streep, Mario Batali, Stephen Colbert, Malcolm Gladwell, Yo-Yo Ma, Mike Nichols, Kristi Yamaguchi, Elizabeth Alexander, Queen Noor and Louise Erdrich have all submitted DNA tests for a new PBS television series FACES OF AMERICA.
Faces of America with Henry Louis Gates, Jr. airs on Wednesdays, February 10 – March 3, 2010 from 8-9 p.m. ET on PBS.
abstract: An effect from anticipation also in hereditary nonpolyposis colorectal cancer families without identified mutations.(Lynch Syndrome)
Note: this would apply to the many with no known mutations in the many genetic syndromes (eg. BRCA, Peutz-Jeghers Syndrome...)
"This observation suggests that anticipation may apply also to families without identified mutations and serves as a reminder to initiate surveillance programmes at young age also in HNPCC families with undefined genetic causes."
Saturday, January 16, 2010
A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer --joint study Japan/U.S.
Note: This abstract is highly technical, but the significance is that there is a focus on clear cell ovarian cancer.
"...Our experiments have revealed strong candidate miRNAs and their target genes that may contribute to the pathogenesis of clear cell ovarian cancer..."
Hereditary breast and ovarian cancer: Referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the
Hereditary breast and ovarian cancer: Referral source for genetic assessment and communication regarding assessment with nongenetic clinicians in the community setting:
2009 Yi and St Louis Ovarian Cancer at OneTrueMedia.com
see the Montage from last year's (2009) ovarian cancer ACOR & friends August weekend
WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.
"One-third of ovarian tumours show loss of WWOX expression, and this loss significantly associates with clear cell and mucinous histology, advanced stage, low progesterone receptor expression and poor survival, suggesting that WWOX status affects ovarian cancer progression and prognosis."
Friday, January 15, 2010
FDA (U.S.)Basics - new website
The tool answers questions such as (and more):
How and where do I find out if a drug is approved for use?
Why are there still food recalls?
How do I report a pet food compliant?
You can also submit your own questions, provide feedback, and view interviews with FDA staff.
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporo
Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women
Urinary angiostatin levels are elevated in patients with epithelial ovarian cancer.
Note: further research required
Immunohistochemical analysis of hMLH1 and hMSH2 proteins in serous ovarian tumours.
Note: Immunohistochemical = tumour sample; hMLH1 and hMSH2 (2 of) Lynch Syndrome genes
"Our results suggest that hMLH1 and hMSH2 proteins may be involved in ovarian carcinogenesis."
AACR upcoming conference: Cancer Epigenetics
"The study of epigenetic mechanisms in cancer, such as DNA methylation, histone modifications, nucleosome positioning and non-coding RNA expression, has revealed a plethora of events that contribute to the neoplastic phenotype through stable changes in the expression of genes critical to transformation pathways...Therefore, improved understanding of normal epigenetic programs is necessary to better understand malignancy-specific epigenetic alterations.....numerous other clinical applications of the field being explored in areas such as cancer screening and early detection, prevention, classification for epidemiology and prognostic purposes, and predicting outcomes after standard therapy."
Exons: Researchers Sequence 'Exomes' Of New Strategy For Finding Disease Genes
"....demonstrated the feasibility and value of a new strategy for identifying relatively rare genetic variants that may cause or contribute to disease....The new strategy involves isolating and sequencing all exons which are the parts of the human genome that contain the information needed to produce proteins, the building blocks of the body. The complete set of exons – referred to as the "exome" – makes up only one percent of the human genome. By selecting only the exome to sequence, the important information about an individual can be obtained at a much lower cost than sequencing a person's entire genome."
2010 Who Is Responsible? The Role of Family Physicians in the Provision of Supportive Cancer Care
Note: the issues from the family physicians' perspective
Editorial: Who Should Follow Our (Cancer) Patients?
Note: Good plain english article generalizing the issues - $$/capacity/knowledge
Thursday, January 14, 2010
abstract : Laparoscopic optical coherence tomography imaging of human ovarian cancer
Note: advances in the imaging of ovarian cancer
Surgery duration linked to infectious complications, hospital stay - Anesthesiology Videos - The Doctor's Channel
not specific to ovarian cancer
full free access: Targeting Insulin and Insulin-Like Growth Factor Pathways in Epithelial Ovarian Cancer
Note: a highly technical paper - look at Table 2; 7.5 = clinical trials link; 8.0 = Conclusion
Contemporary Management of and Future Directions in Ovarian Cancer - Cancer Network
Note: this was posted in November, but I have brought the posting date forward to coincide with other like articles, so both can be viewed at the same time. Access to this article requires that you sign on to the website (free).
full free access: Jan 2/2010 - Targeted Therapy in Ovarian Cancer
Review Article
Targeted Therapy in Ovarian Cancer
Lyndsay J. Willmott and John P. Fruehauf
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA Academic Editor: Charles F. Levenback
full free access: (2010) Germline Mutations and Polymorphisms in the Origins of Cancers in Women
Note: a good explanation in (close to) plain english on a subject that is anything but easy to understand.
Subscribe to:
Posts
(
Atom
)
